New pill aims to shrink hard-to-treat lung tumors
NCT ID NCT05378763
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study tests a new pill, poziotinib, against standard chemotherapy (docetaxel) in people with advanced lung cancer that has a specific genetic change (HER2 mutation). The goal is to see if poziotinib can keep tumors from growing longer than chemo. About 268 adults who have already tried other treatments will take part. The study is currently on hold.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bond Clinic, P.A.
Winter Haven, Florida, 33880, United States
Conditions
Explore the condition pages connected to this study.